{"generic":"Technetium Tc 99m Besilesomab","drugs":["Technetium Tc 99m Besilesomab"],"mono":{"0":{"id":"jxvds0","title":"Generic Names","mono":"Technetium Tc 99m Besilesomab"},"1":{"id":"jxvds1","title":"Dosing and Indications","sub":[{"id":"jxvds1b4","title":"Adult Dosing","mono":"<ul><li>technetium Tc 99m besilesomab has centralized marketing authorization by the European Medicines Agency (EMA) for use in the European Union (EU)<\/li><li>allow an interval of at least 2 days between scintigraphy with other technetium Tc 99m-labelled agents and administration of technetium Tc 99m besilesomab<\/li><li>no established criteria is available to distinguish infection and inflammation using technetium Tc 99m besilesomab imaging<\/li><li><b>Nuclear medicine imaging procedure - Osteomyelitis; Diagnosis:<\/b> 0.25 to 1 mg (400 to 800 megabecquerel) IV (European Medicines Agency-approved dosing)<\/li><\/ul>"},{"id":"jxvds1b5","title":"Pediatric Dosing","mono":"safety and efficacy in pediatric patients less than 18 years not established "},{"id":"jxvds1b6","title":"Dose Adjustments","mono":"<ul><li><b>renal impairment:<\/b> no dose adjustment necessary<\/li><li><b>hepatic impairment:<\/b> no dose adjustment necessary<\/li><li><b>elderly:<\/b> no dose adjustment necessary<\/li><\/ul>"},{"id":"jxvds1b7","title":"Indications","mono":"<b>Non-FDA Labeled Indications<\/b><br\/>Nuclear medicine imaging procedure - Osteomyelitis; Diagnosis<br\/>"}]},"3":{"id":"jxvds3","title":"Contraindications\/Warnings","sub":[{"id":"jxvds3b9","title":"Contraindications","mono":"<ul><li>human anti-mouse antibody (HAMA), positive result on screening test<\/li><li>hypersensitivity to other murine antibodies<\/li><li>hypersensitivity to technetium Tc 99m besilesomab or any component of the product<\/li><li>pregnancy<\/li><\/ul>"},{"id":"jxvds3b10","title":"Precautions","mono":"<ul><li>anaphylactic or anaphylactoid reactions may occur; appropriate facilities and personnel should be available during administration.<\/li><li>carcinoembryonic antigen (CEA)-expressing tumors; false-positive findings may occur<\/li><li>concurrent administration of substances which inhibit inflammation or affect the hematopoietic system (eg, antibiotics and corticosteroids); false-negative findings may occur; use not recommended with technetium Tc 99m besilesomab or a short time before administration.<\/li><li>hereditary problems of fructose intolerance; use not recommended due to the sorbitol component<\/li><li>malignancies, hematological, including myeloma; false-positive findings may occur<\/li><li>neutrophil defects, diseases involving; false-positive findings may occur<\/li><\/ul>"},{"id":"jxvds3b11","title":"Pregnancy Category","mono":"Unknown<br\/>"},{"id":"jxvds3b12","title":"Breast Feeding","mono":"Unknown<br\/>"}]},"5":{"id":"jxvds5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Cardiovascular:<\/b>Hypotension (1% to less than 10%)<\/li><li><b>Immunologic:<\/b>Antibody development (14%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Immunologic:<\/b>Hypersensitivity reaction (0.1% to less than 1%)<\/li><li><b>Other:<\/b>Anaphylaxis (0.01% to less than 0.1%)<\/li><\/ul>"},"6":{"id":"jxvds6","title":"Drug Name Info","sub":{"2":{"id":"jxvds6b19","title":"Class","mono":"Diagnostic Agent, Radiopharmaceutical Imaging<br\/>"},"3":{"id":"jxvds6b20","title":"Regulatory Status","mono":"RX<br\/>"}}},"9":{"id":"jxvds9","title":"Administration","mono":"<b>Intravenous<\/b><br\/><ul><li>use proper procedures for handling and disposal of radiopharmaceuticals<\/li><li>radionucleotide is not part of the kit<\/li><li>inject 5 mL NS into vial labelled Solvent for Scintimun and shake smoothly<\/li><li>transfer 1 mL of Solvent for Scintimun into vial of besilesomab and swirl carefully without shaking<\/li><li>place vial of reconstituted besilesomab into appropriate lead shielding container and inject 2 to 7 mL of pertechnetate Tc 99m into vial and swirl carefully without shaking<\/li><li>activity must be between 400 and 1800 megabecquerel in a total volume of 3 to 8 mL<\/li><li>solution for injection is ready for use 10 minutes after radiolabeling is complete<\/li><li>do not store reconstituted and radiolabeled product above 25 degrees C<\/li><li>protect final radiolabeled injection solution from light and administer IV within 3 hours of preparation<\/li><li>ensure patients are well hydrated to obtain the best quality images and to reduce bladder radiation exposure<\/li><\/ul>"}}}